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Abstract
Background: Libya is one of the largest countries in Africa and has the longest coast in the Mediterranean basin
facing southern Europe. High rates of prevalence of viral hepatitis have been observed in various regions in Africa,
but the prevalence in Libya is not well documented. We report on a large-scale nationwide study that evaluated
the epidemiology of hepatitis B and hepatitis C in Libya and assessed the risk factors involved.
Methods: A cross-sectional study was carried out in 2008 on 65,761 individuals all over Libya. The country was
divided into 12 regions according to the population density and sampling within each region was carried out under
the supervision of the National Centre for Prevention of Infectious Diseases. Serum samples were collected from
both males and females of all ages in both urban and rural areas and tested for HBsAg for hepatitis B and anti-HCV
antibody for hepatitis C. Prevalence rates were determined in regions and in different groups and correlated with
different demographic and risk factors involved in the spread of these viruses.
Results: The prevalence of hepatitis B and hepatitis C viruses varied regionally across the country. The overall
prevalence of hepatitis B was 2.2% (95% CI 2.1%−2.3%) and was higher among males than females (1.4:1.0).
Hepatitis C virus (HCV) prevalence was 1.2% (95% CI 1.1−1.3) and it increased gradually after the age of 30 years
(0.7−0.9% for < 30 years; 3.6% for ≥ 60 years). Prevalence of HBsAg was 0.8−0.9% below the age of 10 years, and
higher but similar in older age groups (2.3−2.7%). There was an association between literacy and prevalence of
hepatitis, particularly for HCV. Hospital admission, surgical operation, blood transfusion, and intravenous drug use
were the main risk factors, and they were associated independently with a higher prevalence rate of viral hepatitis.
Conclusions: Libya may be considered an area of low-intermediate endemicity for hepatitis B virus infection, with
lower rates in young age groups, and an area of low endemicity for hepatitis C. The prevalence of hepatitis B and C
across Libya is not homogeneous, with indications of the effect of the higher rates in some neighbouring countries.
Libya should adopt full coverage national plans and guidelines to face the future consequences of viral hepatitis,
particularly hepatitis C virus.
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Background
Hepatitis B and C viruses (HBV and HCV) are the major
causes of liver diseases in the world. The relative import-
ance of HBV and HCV infections varies greatly from one
part of the world to another and changes over time [1].
Worldwide, over two billion people are infected by HBV
alone, of whom about one million die annually. Hepatitis
C virus affects about 200 million people [2]. However, in
many countries its prevalence is expected to surpass that
of hepatitis B, particularly among certain risk groups that
are vulnerable to both hepatitis B and C viruses [3].
The endemicity of HBV infection varies greatly over the
world, from highly endemic areas (> 8% infection rate), to
intermediate (2−8%) and low endemicity areas (< 2%).
Africa is among the highly endemic areas, but some
countries in the north fall in the intermediate category, with
an average rate of about 7%, whereas most regions of west
and east Africa are highly endemic areas with chronic infec-
tion rates of 7−10% [4]. In some countries, such as Senegal,
a large part of the population will be exposed in the course
of their lives to HBV and become infected [5]. All of central
and southern Africa is also in the high endemicity category
[6]. Few studies evaluated the status of HBV in Libya. In
2000, Daw et al. [7] reported a HBV prevalence of 10%
among hospital health-care workers and that infection was
associated with certain occupational risk factors.
Hepatitis C virus infection is a major public health
problem [8,9]. African countries have among the highest
prevalence rates of HCV in the world, ranging from 1 to
26% [10,11]. More than 28 million people are chronically
infected with HCV in this continent, and it is difficult to
speculate about current and future trends [3,12]. In
Libya, one study reported that the prevalence of HCV
among different populations varied according to the risk
factor involved [13]. Recently, a comprehensive study
was carried out on HCV genotypes in Libya. Hepatitis C
virus genotype 4 was the predominant one, followed by
HCV genotype 1 and then other less common genotypes
[14]. However, further studies are needed to clarify the
magnitude and impact of HCV in Libya.
Viral hepatitis has tremendous socioeconomic, health-
care and even political repercussions. A better under-
standing of the epidemiology of viral hepatitis and the
risk factors involved is among the priorities of any na-
tion [15,16]. Reliable epidemiological data on prevalence
rates and transmission routes [17,18] of viral hepatitis
are essential for designing national control policies. The
epidemiological data in Africa are scanty and vary greatly
from one region to another [4]. Therefore, each country
should adopt its own strategy to combat viral hepatitis.
Libya has an area of 1,775,500 km2 and a population
reported in mid 2006 as 5,323,991, giving a population
density of 2.9 persons per km2. The country boasts the
highest literacy and educational enrolment in North
Africa and among the Arab nations [19,20]. Life expectancy
(73 years) and health-adjusted life expectancy (64 years) are
among the best in the Middle East and North Africa
[19,21]. Nevertheless, Libyan health services have been
hampered by bureaucracy and lack of proper long-term
planning [20,22]. Both Libyan and international medical ex-
perts have voiced concerns about the potential for increases
in infection, particularly viral hepatitis and AIDS [23,24].
Recent data on the prevalence of hepatitis B and C
viruses and risk factors among the Libyan population are
lacking. Such data are important for understanding the
burden of viral infection and for predicting future trends.
Implementation of surveillance to guide public health pol-
icy is needed to efficiently control viral hepatitis spread in
this country, and this requires reliable epidemiological
data. In this comprehensive nationwide study we deter-
mined the prevalence of hepatitis B and C virus infections
among the Libyan population and analysed the risk factors.
Methods
Study population
We conducted a national cross-sectional study stratified
by region and age. The sample size in each region was set
ahead of the survey and recruitment continued until the
sampling teams fulfilled the required sample size. Those
enrolled from each region were selected randomly. Re-
gional representativeness was fulfilled by classifying the
country into 12 regions including all administrative divi-
sions and sampling based on population proportions.
Sample sizes of males, females and age strata were deter-
mined by multi-stage cluster sampling in each region pro-
portional to regional populations according to the latest
national census in 2003–2004. Teams of medical doctors
and nurses established the sampling frames and collected
the information and samples in all the regions as described
in Table 1. The following targeted age strata were selected:
– < 6 years: Pre-school children (maternal and child
care centres);
– 7–19 years: School age below university level
(primary, preparatory and high schools);
– 20–49 years: University graduate and post graduate
students (universities and health services centres);
– ≥ 50 years: Employed and retired personnel
(different community and governmental sectors).
Demographic and epidemiological data questionnaire
Sample size calculations were based on the prevalence of
HCV and HBV infections in prior studies in Libya. To
detect a two-fold increase in prevalence among the
lowest prevalence expected for HCV 1/1000 in each age
group as compared with the next age, a sample of
25,476 has a power of 80% (beta error <0.2) to detect
this difference at the alpha = 0.05 level (one-sided). A
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total sample of 51,000 would allow estimation of these
parameters independently for males and females.
Individuals confirmed to be infected with HCV were re-
ferred to the main teaching hospitals in the major regions:
Tripoli Central Hospital and Tripoli Medical Centre for
western and central regions, Benghazi Medical Centre for
the eastern regions, and Sebha Medical Centre for Fezzan
area. These hospitals receive all individuals who test posi-
tive for anti-HCV, HBV or HIV from all over the country
as a policy run under the control of the Libyan National
Health Authority.
The questionnaire sought information about age, gender,
education, residence and occupation, as well as history of
major invasive interventions, use of recreational intraven-
ous drugs, and promiscuous sexual practices. The ques-
tionnaire was completed by each participant and those of
a younger age were helped by their parents in the presence
of medical doctors and social assistants, who recorded the
needed information and coded the questionnaire.
Figure 1 Map of Libya showing the prevalence of hepatitis B and C infections by region.
Table 1 Numbers of samples collected from the 12 Libyan
regions
Region Number Percent Ratio*
Albatnan 4996 7.6 1.80
Aljabal Alakhdar 5944 9.0 1.10
Benghazi 6938 10.6 1.10
Ajdabia 4963 7.5 1.10
Sirt 3871 5.9 1.75
Misrata 4966 7.6 1.90
Almergeb 4913 7.5 1.10
Tarhuna 5023 7.6 1.10
Tripoli 8013 12.2 1.10
Alzawia 5022 7.6 1.80
West mountain 5752 8.7 1.10
Fezzan 5360 8.2 1.90
Total sample 65761 100 1.10
*Ratio of individuals testing positive for hepatitis B and C viruses to the total
population in each region.
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Laboratory tests
A blood sample of 5−10 ml was collected and transported
immediately to the local laboratory in a general hospital
within the same region. Serum was prepared and stored
at −20°C until tested as previously described [14].
All samples were tested for HBsAg and anti-HCV
markers by using a third-generation enzyme immuno-
assay (Axsym; HCV EIA 3.0; Abbott Laboratories, Ab-
bott Park, Illinois, and HBsAg, Axsym) as previously
published [14]. Samples that were positive for anti-HCV
were retested by the same method, and only if the retest
was positive were they considered as positive.
Statistical analysis
Data were coded and entered into a data base, which
was then cleaned and verified. Data were analysed by
using the Chi-square test with Yates' correction or Stu-
dent's t-test for univariate analysis. Multivariate analysis
was performed by using logistic regression, with anti-
HCV serologic results as the dependent variable (SPSS,
Inc., Chicago, Illinois). Prevalence estimates are reported
with 95% confidence intervals (CI) determined by using
the Poisson distribution approximation [18]. A type I
error of α = 0.05 was assumed. Sample weighting was
later performed and a weight was calculated according
to age and sex within each region.
Ethical considerations
The study was approved by the Libyan National Ethical
Committee (Approval No. LY NS; HV299789). It was
conducted in accordance with the Helsinki Declaration
[25] and under the supervision of the Libyan Centre for
Disease Control. All participants signed an informed
consent form witnessed by the local health office before
collection of data and blood samples. The questionnaire
used to collect demographic and epidemiological data
(Additional file 1: Table S1) was anonymous and linked
to the blood sample tube only by a code.
Results
The overall prevalence of HBsAg positivity was 2.2%
(95% CI 2.1%−2.3%). The prevalence varied from one re-
gion to another (Figure 1). The rate was highest in Sirt
(6.6%) and Tarhuna (3.4%), and lowest in Aljabel Alakhdar
(1.0%), Benghazi (1.0%), and Ajdabia (1.4%). The overall
prevalence of HCV was 1.2% but it varied from one region
to another (Figure 1). The highest rates were in Fezzan
(2.2%) and Albatnan (1.8%) and the lowest were in Misrata
(0.6%), Sirt (1.0%) and Western Mountain (1.1%). The rate
of HBV prevalence was significantly higher in males (2.6%;
95% CI 2.4−2.7) than in females (1.8%; 95% CI 1.6−1.9).
The probability of being HBsAg positive was 1.4 times
higher among males than females.
The overall unweighted prevalence of HCV was 1.2%
(95% CI 1.1−1.3), and it rose to 1.3% after weighting. For
those aged > 20 years, the unweighted and weighted per-
centages were not significantly different (1.5% and 1.6%,
respectively). The prevalence rate was slightly higher
Figure 2 Prevalence of hepatitis B and C infections by age,
Libya, 2008.
Table 2 Association between hepatitis B and C virus
infections and influencing factors among the Libyan
population
HCV HBsAg
OR 95.0% C.I. OR 95.0% C.I.
Lower Upper Lower Upper
Age group (years) relative to < 6
6-10 0.74 0.46 1.18 1.21 0.79 1.86
11-20 0.91 0.67 1.24 3.36 2.5 4.52
21-30 0.88 0.63 1.22 3.01 2.21 4.1
31-40 1.41 1.01 1.96 3.14 2.28 4.32
41-50 1.87 1.32 2.64 3.77 2.7 5.26
51-60 2.36 1.65 3.37 3.7 2.59 5.28
61-70 3.27 2.17 4.93 3.34 2.13 5.24
>70 3.32 2.01 5.49 5.69 3.54 9.15
Males vs females 0.86 0.74 0.99 1.51 1.35 1.68
Hospital admission 1.32 1.09 1.61
Dental procedure 0.84 0.71 0.99 0.85 0.76 0.96
Blood transfusion 1.55 1.22 1.97
Intravenous drug use 6.41 2.27 18.07 0 0 -
Surgery 1.35 1.08 1.67
Family HBV 1.52 1 2.3 1.97 1.46 2.64
Haemodialysis 4.37 1.71 11.2
Contact with HBV 1.66 1.23 2.23
Skin piercing 1.36 1 1.83
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among females than males but the difference was not sta-
tistically significant. The prevalence rates weighted for
other factors (age group, education, marital status, type of
dwelling, and risk exposure) are shown in Additional file 2:
Table S2.
Figure 2 shows the prevalence of HBV and HCV among
the Libyan population according to age. The prevalence of
anti-HCV was stable at 0.8−0.9% until the age of 30 years,
after which it rose steadily, reaching 2.7% in those above
the age of 50 years. In contrast, the prevalence of HBsAg
was lowest in the youngest age group (0.9%), and in the
older groups it fluctuated between 2.0% and 2.9% without
any evident temporal trend. However, it rose sharply after
the age of 70 years.
The overall prevalence rates of HCV in males and
females were similar (1.1% and 1.3%, respectively). The
mean ages of anti-HCV positive females (31.7 ± 18.4 years)
and males (35.6 + 20.9 years) were significantly higher
(p < 0.001) than those of HBsAg positive females (26.3 +
16.8 years) and males (30.0 + 17.6 years). The mean age of
HCV positive individuals was significantly higher than
that of anti-HCV negative individuals for both males (al-
most 10 years difference) and females (7 years difference).
The mean age of HBsAg positive individuals was also sig-
nificantly higher (but to a lesser degree) among females
(by < 2 years) and males (by < 4 years). More than 50% of
the HBsAg positive individuals and about 40% of HCV
positive cases were below 30 years of age.
The associations between hepatitis B and C virus in-
fections and various factors are shown in Table 2. Hepa-
titis B virus was more prevalent among the illiterate
group (2.9%) than among the literate groups: 1.6% among
postgraduates and 2.3% among preparatory school stu-
dents. The prevalence of HCV was also higher among the
illiterate group (3.1%) whereas in the literate groups it
ranged from 0.9% to 1.1%. The influence of marital status
and living standard on the prevalence of hepatitis B and C
is shown in Figure 3. Hepatitis B was more prevalent
among the widowed, whereas HCV was more prevalent
among single and younger individuals.
Figure 3 Prevalence of hepatitis B and C infections by demographic and social variables, Libya, 2008. A. Gender B. Education C. Marital
Status D. Type of housing.
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We also analysed the influence of risk factors, such as
hospital admission, surgical operation, blood transfusion,
intravenous drug use, and sexual behaviour, on the preva-
lence of hepatitis B and hepatitis C (Figure 4). Hepatitis B
virus was most prevalent among those with previous
surgical operations (2.4%) or history of hospital admission
(2.4%), followed by blood transfusion (2.1%) and pro-
miscuous sexual behaviour (1.6%). Hepatitis C was most
prevalent among intravenous drug users (7.4%) and less
prevalent but still substantial in those undergoing blood
transfusion (2.7%), surgical operation (2.3%) or hospital
admission (1.9%).
Table 3 shows the distribution of the estimated sero-
prevalence of HBV and HCV according to demographic
characteristics. There were minimal differences in the esti-
mated number of cases between males and females for
HCV, but more than 60% of the estimated number of
HBsAg positive individuals were males. Over 50% of them
were below 30 years old, and about 40% of HCV cases
were also below that age. In terms of educational level, the
highest prevalence rate of infection was among illiterates
for both viruses (weighted prevalence 2.6% for HBsAg,
representing 12.3% of all estimated cases, and 3.0% for
HCV, representing 21.8% of all estimated cases).
Discussion
The few studies on the prevalence of hepatitis B and C
viruses in Libya examined specific population groups,
such as parturient women and their newborns [26],
healthcare workers, blood donors, transfusion patients
[13] and hemodialysis patients [27], or other issues such
as prevalence of genotypes [14]. However, none of these
studies lend themselves to extrapolation to the general
population, and our study, the first of its kind in Libya
and the largest in Africa, was done to provide a basis for
prioritising public health measures in Libya.
In the European Mediterranean countries, the overall
prevalence of HBV ranges between 2.5% and 3.5% [28,29].
In contrast, North Africa is overall an area of relatively
high HBV endemicity. Tunisia, Algeria and Morocco fall
in the intermediate category, with current infection rates
of about 7% [30]. But Egypt is classified among the highest
endemicity countries, along with Sudan, Chad and Niger,
all of which neighbour Libya [31,32]. The lower preva-
lence rate of HBV we observed (2.2%) classifies Libya in
the lower part of the low-intermediate endemicity class
(2−7% category). This lower rate could be due to the
better socioeconomic conditions and the early efforts by
the National Prevention Program of Infectious Diseases
in Libya. Vaccination against HBV infection has been
strongly encouraged and offered free of charge in Libya
since 1989, and in 1991 it became compulsory for in-
fants 3 months of age and children 12 years of age.
Hepatitis C is an emerging problem among the
Mediterranean countries, where the estimated preva-
lence ranges from 1.0−2.6%, and isolated areas in Italy
and Greece have rates of 7−20% among the general
adult population [33,34]. A similar picture was also found
in Tunisia and Morocco, where the rates ranged from 1.7
to 2.9%, with higher rates in some regions [35,36]. Hepa-
titis C virus screening and surveillance is minimal at the
national level in these countries. In Libya, a study
Figure 4 Prevalence of hepatitis B and C infections by risk factors, Libya, 2008 *Statistically significant at 0.05.
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conducted between 1991 and 2001 indicated that the
prevalence of HCV ranged from 1.2% to 1.6% among
blood donors and healthy individuals but was much
higher (20.5%) among hospital personnel [13]. The 1.2%
rate we observed in our country-wide study classifies
Libya as a low endemicity country. Libya has made
screening mandatory for all blood donors, pregnant
women, and patients at high risk of having surgery, and
has introduced a national registry system covering all
positive individuals.
We were not surprised by the substantial regional vari-
ation in prevalence rate in Libya. Such variation has also
been reported in other Mediterranean countries, such as
Italy, Greece and Spain [37-39]. The variation observed
in Libya is probably related to different factors, including
socioeconomic conditions, but one particular observa-
tion is noteworthy. The prevalence of HCV was highest
in the southern region of Fezzan (2.08%) and the eastern
region of Albatnan (1.77%). The high prevalence in the
southern region could be related to its proximity to sub-
Saharan countries and the hosting of many African im-
migrants. Likewise, the eastern region of Albatnan
borders Egypt, which has the highest prevalence rate of
HCV in the world [40,41], and from where many
workers, both legitimate and illegal, come to Libya.
In Libya, the prevalence of HBV was low in children < 10
years of age (0.8%), and in the other age groups it ranged
from 2.0 to 2.9%. In most other African countries the
prevalence is high among infants and increases rapidly
until the age of 30 years, and it rises even higher among
those over forty years old [5,6,42]. The lower rate in the
Libyan population could be due to the compulsory chil-
dren vaccination program, which was introduced earlier in
Libya than in other African countries.
The overall prevalence of HCV in our study was not
significantly different between females and males, and it
increased gradually after the age of 30 years. This is in
agreement with previous studies carried out in Libya,
which showed a peak in the prevalence of HCV among
those 46−55 years old [13]. Other studies, particularly
from North America, also showed the highest prevalence
in the 30−49 year age group in all racial groups [43,44].
We also analysed the risk factors associated with HBV
and HCV infections. The influence of risk factors on the
prevalence rate was evident for HCV. The prevalence
rate among those with risk factors ranged from 1.9 to
7.4%, whereas among those without risk factors it was
1.3% (p < 0.025). The most prominent risk factor was
intravenous drug use, with 7.4% of intravenous drug
users testing positive for HCV. In this context, it is im-
portant to note that active drug users are less likely to
participate in health surveys, and the actual overall preva-
lence rate is likely higher than the observed rate [45,46]. A
recent study on ~1200 Libyan patients chronically in-
fected with HCV correlated genotypes with risk factors.
That study indicated that recent drug use was significantly
linked to emergence of new genotypes, lending further
credence to the role of intravenous drug use in HCV
transmission in Libya [13]. Accordingly, we expect that
Table 3 Number of persons chronically infected by HBV
and of anti-HCV positive individuals in Libya according







n % n %
Total 107,848 100 68,275 100.0
Gender
Females 42,297 39.2 34,845 51.0
Males 65,551 60.8 33,430 49.0
Age groups
≤ 5 4,861 4.5 4,699 6.9
6−10 4,110 3.8 3,881 5.7
11−20 26,148 24.2 8,889 13.0
21−30 26,153 24.2 10,147 14.9
31−40 20,139 18.7 13,966 20.5
41−50 11,436 10.6 9,738 14.3
51−60 6,856 6.4 6,633 9.7
61−70 3,613 3.4 6,415 9.4
≥71 4,532 4.2 3,907 5.7
Education
Below school age 4,957 4.6 5,235 7.7
Illiterate 13,318 12.3 14,850 21.8
Preparatory 34,927 32.4 20,685 30.3
High school 34,389 31.9 17,214 25.2
University 16,118 14.9 7,544 11.0
Post graduate 1,769 1.6 981 1.4
Unknown 2,370 2.2 1,766 2.6
Marital status
Married 39,844 36.9 32,605 47.8
Single 42,551 39.5 17,845 26.1
Widowed 1,425 1.3 3,403 5.0
Divorced 913 0.8 470 0.7
Below age 21,434 19.9 12,828 18.8
Unknown 1,681 1.6 1,124 1.6
Type of dwelling
Villa 13,545 12.6 6,944 10.2
Apartment 10,491 9.7 10,480 15.3
Rural house 80,646 74.8 49,398 72.4
Other 118 0.1 104 0.2
Unknown 3,048 2.8 1,349 2.0
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the prevalence of HCV may increase in Libya because
there is consensus that HCV-infected populations are
heavily weighted towards intravenous drug use world-
wide [47-49].
Our findings show that the prevalence rates of HBV and
HCV in Libya are relatively low, and this could be an indi-
cator of the success of the national efforts to control these
infections. However, we only assessed a marker of the
prevalence of HBV chronic infection (HBsAg), which rep-
resents the reservoir of infection and of future complica-
tions (cirrhosis and liver cancer). We did not estimate the
proportion of those who had ever been infected in Libya,
which can be estimated by testing for serum anti-HBc
antibodies. Moreover, the higher rates in regions bordering
high endemicity countries and the poorly controlled state
of these borders can lead to an increase in prevalence, es-
pecially during this time when the country as whole is ex-
periencing many difficulties. Continuous surveillance and
maintenance of the national program for combating hepa-
titis are essential, and further studies are needed, particu-
larly on co-infection with HIV, which is a problem in this
region. Our findings would be useful for making esti-
mates and projections about the overall disease burden,
including the complications of hepatitis infection, such
as cirrhosis, liver failure, and hepatocellular carcinoma
[50]. Recently, El-Bouzedi [51] constructed a mathemat-
ical model using published epidemiological data on viral
hepatitis to estimate the future consequences of hepatitis
infection in Libya. Such modelling will inform health pol-
icy, resource allocation and healthcare delivery and may
improve the management of patients with viral hepatitis.
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